Navigation Links
Halo Pharmaceutical Completes $14.6 Million in Financing from The Provident Bank
Date:4/22/2009

WHIPPANY, N.J., April 22 /PRNewswire/ -- Halo Pharmaceutical, this week announced that it has completed $14.6 million in financing from The Provident Bank to expand its operations.

Headquartered in Whippany, Halo is a privately held full-service, specialty pharmaceutical company. Halo provides state-of-the-art contract manufacturing, early stage formulation development and laboratory services to the pharmaceutical and related industries.

"Provident is a respected local bank that understands the New Jersey market and the needs of New Jersey's pharmaceutical companies. That's why we chose to go to them for financing," said Mohd Asif, Halo's Chief Financial Officer. "Provident understands that providing the kind of financing that assists local companies helps keep jobs in the Garden State and even helps create jobs here in the future. We look forward to an ongoing close relationship with them."

"We are excited to be working with Halo," said Keith Stinchcomb, Provident vice president and team leader of middle market lending. "At Provident, we focus on building strong relationships with our clients so we can best meet their financial needs. We look forward to continuing to work with Halo as they grow."

Halo's Whippany facilities encompass more than 200,000 sq. ft. and include an array of capabilities. For information about Halo, visit www.halopharma.com or contact Mohd Asif at (973) 428-4013.

For more information about Provident, contact Keith Stinchcomb at (973) 644-5408 or The Provident Bank at 800-448-PROV (7768).

About Halo Pharmaceutical

Halo Pharmaceutical, headquartered in Whippany, NJ, is a specialty pharmaceutical company engaged in pharmaceutical branded product lifecycle management. The company's strategy is to acquire products that are late in their lifecycle and for which lifecycle extension is possible through sustained release formulation development; the addition of appropriate dosage forms and strengths; the development of new indications; and new approaches to promotion of the brands. Halo also offers full service state-of-the-art contract manufacturing in a wide range of dosage forms, formulation and analytical method development from pre-clinical through phase III, and laboratory testing services to the pharmaceutical and related industries. Halo is currently a supplier of choice to a number of large and medium size brand pharmaceutical companies for important lifecycle products. Contract manufacturing capabilities include the ability to conduct aseptic semi solids manufacturing and filling, granulation, blending, tableting, coating and packaging. DEA Schedule 2 to 5 products can also be manufactured and packaged. Halo also has related warehousing and distribution operations. Halo Pharmaceutical is a privately-held company.

About The Provident Bank

With $4.2 billion in deposits, The Provident Bank serves its customers via a network of 82 branches throughout northern and central New Jersey. The Provident Bank is the wholly owned subsidiary of Provident Financial Services, Inc. (NYSE: PFS), which reported assets of $6.6 billion as of December 31, 2008.


'/>"/>
SOURCE Halo Pharmaceutical
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Lotus Pharmaceuticals, Inc. Reports Strong 2008 Financial Results
2. Genesis Pharmaceuticals Announces the Launch of Three TCM Products
3. Celator(R) Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research
4. WellSpring Pharmaceutical Corp. Emetrol(R) Consumer Brand Achieves Number One Position in Anti-Nausea Category
5. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Oral Picoplatin Demonstrating Bioavailability
6. Tianyin Pharmaceutical Co. Inc.s Ginkgo Mihuan Oral Solution Completes 2009 Tenders
7. Par Pharmaceutical Enters Into Agreement With Reliant Pharmaceuticals to Settle Patent Litigation Over Rythmol(R) SR
8. AUDIO from Medialink and Forest Pharmaceuticals: FDA Approves Lexapro for Major Depressive Disorder in Adolescents
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Halo Pharmaceutical Welcomes Dr. George Bobotas as Its Chief Scientific Officer
11. ISTA Pharmaceuticals Announces Conference Call and Webcast of First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2017)... Greenwich, Connecticut (PRWEB) , ... September 22, 2017 ... ... to conquering Lyme and other tick-borne diseases through research, education and awareness, today ... , A noted immunologist and microbiologist, Dr. Sellati has more than 20 ...
(Date:9/21/2017)... Angeles, CA (PRWEB) , ... September 21, 2017 ... ... a lunch and learn with Infinity Behavioral Health Services for professionals in the ... in a Commercial Payer Audit . , Insurance companies and state and ...
(Date:9/21/2017)... ... September 21, 2017 , ... ... or exercise more try taking a more holistic approach and use natural alternatives ... Amazon essential oil collection is certified USDA guaranteeing that, the new line of ...
(Date:9/21/2017)... ... September 21, 2017 , ... A new addiction treatment ... a time when Virginia faces an opioid epidemic. , Last year, ... of 38 percent from 2015, underscoring the need for additional addiction treatment options. ...
(Date:9/20/2017)... ... September 20, 2017 , ... Reflections Recovery Center, a men-only ... The Joint Commission for chemical dependency and behavioral health services. , The Joint ... organizations that meet the commission’s rigorous standards. Accreditation by The Joint Commission is ...
Breaking Medicine News(10 mins):
(Date:9/12/2017)... 2017  Consumer reviews on the independent review site Consumer ... one company for hearing aids, ranking it higher than Miracle ... ... Consumers For Hearing Aids ... an online store that provides high performance, state-of-the-art, German-engineered hearing aids ...
(Date:9/9/2017)... Sept. 9, 2017  Eli Lilly and Company (NYSE: ... secondary endpoint data for lasmiditan, an investigational, oral, first-in-class ... statistically significant improvements compared to placebo in the Phase ... at the 18th Congress of the International Headache Society ... "The data presented today demonstrate lasmiditan,s potential to reduce ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
Breaking Medicine Technology: